Isracann Financial Statements From 2010 to 2024
Isracann Biosciences financial statements provide useful quarterly and yearly information to potential Isracann Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Isracann Biosciences financial statements helps investors assess Isracann Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Isracann Biosciences' valuation are summarized below:Isracann Biosciences does not presently have any fundamental trends for analysis.
This module can also supplement various Isracann Biosciences Technical models . Check out the analysis of Isracann Biosciences Correlation against competitors.
Check Isracann Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Isracann Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Isracann financial statements analysis is a perfect complement when working with Isracann Biosciences Valuation or Volatility modules.
Isracann |
Isracann Biosciences Company Current Valuation Analysis
Isracann Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Isracann Biosciences Current Valuation | 2.16 M |
Most of Isracann Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Isracann Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Isracann Biosciences has a Current Valuation of 2.16 M. This is 99.98% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Isracann Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Isracann Biosciences competition to find correlations between indicators driving Isracann Biosciences's intrinsic value. More Info.Isracann Biosciences is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.About Isracann Biosciences Financial Statements
Isracann Biosciences stakeholders use historical fundamental indicators, such as Isracann Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Isracann Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Isracann Biosciences' assets and liabilities are reflected in the revenues and expenses on Isracann Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Isracann Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.